RVT-1401

DRUG2 trials

Sponsors

Immunovant Sciences GmbH

Conditions

Graves' OphthalmopathyMyasthenia Gravis

Phase 2

A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

CompletedNCT03863080

Immunovant Sciences GmbHMyasthenia Gravis

Start: 2019-05-21End: 2020-12-21Updated: 2023-12-20

Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)

CompletedNCT03922321

Immunovant Sciences GmbHGraves' Ophthalmopathy

Start: 2019-04-22End: 2020-05-21Updated: 2022-01-24

Related Papers

ODP509 Proof-of-concept, Multicenter, Open-Label Phase 2a Study of Batoclimab in Active and Moderate-to-Severe Thyroid Eye Disease

Journal of the Endocrine Society2022-11-016 citations